ArticleEuropean journal of medical research2026
CRP-TyG index and risk of new‑onset central retinal artery occlusion and subsequent major adverse cardiovascular and cerebrovascular events: a propensity score‑matched cohort study.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe C‑reactive protein-triglyceride glucose index (CTI), a composite marker of systemic inflammation and metabolic status, has been associated with cardiovascular and cerebrovascular risk. Its role in central retinal artery occlusion (CRAO) and subsequent adverse outcomes is unclear.
methodsIn this cohort study, 122 CRAO patients and 488 matched controls who underwent coronary angiography without coronary artery disease were analyzed. CTI was calculated as 0.412 × ln [CRP (mg/L) + 0.5 × ln [TG × FPG(mg/dL)]. Logistic regression adjusted for demographic, clinical, laboratory, and medication variables was used to explore the relationship between CTI and the risk of CRAO. Restricted cubic spline models assessed the dose-response relationship between CTI and CRAO risk. The primary endpoint was CRAO and the secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs) during the 36‑month follow‑up.
resultsHigher CTI was independently associated with CRAO (adjusted OR = 1.46, 95% CI 1.14-1.88; P = 0.003). Restricted cubic spline analysis identified a CTI threshold of 9.810. CRAO patients with CTI > 9.810 had a higher incidence of MACCEs (31.1% vs. 10.1%, P < 0.001), particularly acute coronary syndromes (20.3% vs. 7.1%, P < 0.001). In subgroup analysis, CRAO patients with CTI > 9.810 had the highest MACCEs rate (40.0%) and significantly greater risk of all‑cause death, stroke, and acute coronary syndromes (all adjusted P < 0.05) compared with other groups. Time‑to‑event analysis revealed that among all groups, CRAO patients with CTI > 9.810 had the shortest median time to MACCEs occurrence at 6 months (IQR, 4-11).
conclusionsElevated CTI is independently associated with increased CRAO risk and predicts higher adverse MACCEs outcomes, suggesting CTI as a potential biomarker for risk stratification and secondary prevention in CRAO patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.